Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/32066
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMAS LOPEZ, MARIA ISABEL-
dc.contributor.authorRamon-Lopez, Amelia-
dc.contributor.authorLacueva, Javier-
dc.contributor.authorMás-Serrano, Patricio-
dc.contributor.authornalda-molina, Ricardo-
dc.contributor.otherDepartamentos de la UMH::Ingenieríaes_ES
dc.date.accessioned2024-05-06T15:00:33Z-
dc.date.available2024-05-06T15:00:33Z-
dc.date.created2017-10-13-
dc.identifier.citationJournal of Pharmaceutical Sciences 107 (2018) 764-769es_ES
dc.identifier.issn1520-6017-
dc.identifier.issn0022-3549-
dc.identifier.urihttps://hdl.handle.net/11000/32066-
dc.description.abstractThe purpose of this study was to evaluate the area under the concentration-time curve (AUC) ratio as an optimal indicator of the pharmacokinetic advantage during hyperthermic intraperitoneal perioperative chemotherapy. The impact on the AUC ratio on the variables related to the calculation of systemic drug exposure, instillation time, and peripheral drug distribution was evaluated through simulations as well as through a retrospective analysis of studies published in the literature. Both model simulations and the retrospective analysis showed that the 3 variables evaluated had an impact on the AUC ratio value if the complete systemic exposure was not fully considered. However, when that complete systemic exposure was considered, none of these variables affected the AUC ratio value. AUC ratio is not a characteristic parameter of a drug if the calculated systemic drug exposure is not complete. Thus, AUC ratio is not valid for comparing the pharmacokinetic advantage of 2 drugs, and it should not be employed to prove whether a drug can be used in hyperthermic intraperitoneal perioperative chemotherapy safely with regard to toxicity. As an alternative, the study of the absorption rate constant and the bioavailability are proposed as the true and independent parameters that reflect the amount of drug absorbed. © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent6es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectClinical pharmacokineticses_ES
dc.subjectSimulationses_ES
dc.subjectCancer chemotherapyes_ES
dc.subjectabsorptiones_ES
dc.subjectMathematical modelses_ES
dc.subjectClearancees_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::62 - Ingeniería. Tecnologíaes_ES
dc.titleSuitability of the AUC Ratio as an Indicator of the Pharmacokinetic Advantage in HIPECes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.xphs.2017.10.008es_ES
Appears in Collections:
Artículos Ingeniería


no-thumbnailView/Open:

 Articulo final.pdf



552,44 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???